Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Inflammatory Bowel Diseases

Free Subscription 02.11.2026 3 Aliment Pharmacol Ther 1 Am J Gastroenterol 1 Clin Gastroenterol Hepatol 2 Eur J Gastroenterol Hepatol 2 Gastroenterology 7 Inflamm Bowel Dis 5 J Crohns Colitis 1 J Immunol 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aliment Pharmacol Ther

1. ROBERTS C, Smith R, Odeh S, Kuk N, et al
   Maternal Obesity Is Associated With Adverse Pregnancy Outcomes in Inflammatory Bowel Disease: A Matched Electronic Health Record Cohort Study.
   Aliment Pharmacol Ther. 2026 Oct 28. doi: 10.1111/apt.71073.
   PubMed         Abstract available
   
   
2. YOGAKANTHI S, Schulberg J
   Editorial: Seeing Through the Wall-Can Intestinal Ultrasound Guide Upadacitinib Dosing in Crohn's Disease?
   Aliment Pharmacol Ther. 2026 Oct 26. doi: 10.1111/apt.71076.
   PubMed        
   
   
3. MOHAMEDI JA, Hoffert Y, Geukens N, Rahier JF, et al
   Baseline Clearance and Early Troughs Identify Candidates for Early Therapeutic Drug Monitoring During Infliximab Induction in Inflammatory Bowel Disease.
   Aliment Pharmacol Ther. 2026 Oct 25. doi: 10.1111/apt.71062.
   PubMed         Abstract available
   
   

   
   Am J Gastroenterol

4. CALDERA F, Hayney MS, Zhang X, Kappelman MD, et al
   Safety of Live Vaccine Administration in Patients with Inflammatory Bowel Disease on Immune-Modifying Therapy.
   Am J Gastroenterol. 2026 Oct 27. doi: 10.14309/ajg.0000000000004238.
   PubMed        
   
   

   
   Clin Gastroenterol Hepatol

5. PAL P, Pooja K, Naaz SM, Marri UK, et al
   Endoscopic Balloon Dilation Versus Endoscopic Stricturotomy for Short Crohn's Disease Strictures: The BEST-CD Randomized Trial.
   Clin Gastroenterol Hepatol. 2026 Oct 28:S1542-3565(26)00813.
   PubMed         Abstract available
   
   

   
   Eur J Gastroenterol Hepatol

6. ISMAIL A, Lahtiharju T, Savola P, Helin T, et al
   Anemia in inflammatory bowel disease: despite declining rates still a remarkable burden.
   Eur J Gastroenterol Hepatol. 2026 Oct 30. doi: 10.1097/MEG.0000000000003318.
   PubMed         Abstract available
   
   
7. KAUR A, Verma A, Chan T, Evans J, et al
   Differential efficacy of interleukin-23 pathway inhibitors in ulcerative colitis according to disease extent: a systematic review and meta-analysis of randomized trials.
   Eur J Gastroenterol Hepatol. 2026 Oct 27. doi: 10.1097/MEG.0000000000003316.
   PubMed         Abstract available
   
   

   
   Gastroenterology

8. RUBIN DT
   Building a Better Model for Fecal Calprotectin Monitoring in Inflammatory Bowel Disease: Room for Some Home Improvement.
   Gastroenterology. 2026 Oct 16:S0016-5085(26)07350.
   PubMed        
   
   
9. TURNER D, Kenigsberg S, Plotkin L, Aharoni-Frutkoff Y, et al
   TASTY AND HEALTHY DIET REDUCES FECAL CALPROTECTIN IN HIGH-RISK FIRST-DEGREE RELATIVES OF PATIENTS WITH CROHN'S DISEASE: PIONIR RANDOMIZED CROSSOVER TRIAL.
   Gastroenterology. 2026 Oct 26:S0016-5085(26)07729.
   PubMed         Abstract available
   
   

   
   Inflamm Bowel Dis

10. UMAR N, Wambua S, Harvey P, Adderley NJ, et al
    Fecal calprotectin testing for inflammatory bowel disease in patients presenting with lower gastrointestinal symptoms: a retrospective primary care cohort study in the United Kingdom.
    Inflamm Bowel Dis. 2026 Oct 29:izag218. doi: 10.1093.
    PubMed         Abstract available
    
    
11. CASSINOTTI A, Saibeni S, Cannatelli R, Michelon M, et al
    Comparing real-world continuous clinical remission rates of anti-tumor necrosis factor, vedolizumab, ustekinumab, tofacitinib, and upadacitinib in ulcerative colitis.
    Inflamm Bowel Dis. 2026 Oct 29:izag229. doi: 10.1093.
    PubMed         Abstract available
    
    
12. HRADSKY O, Duricova D, Lukas M, Nedbalova L, et al
    Comparison of risankizumab and upadacitinib treatment persistence according to disease location in patients with Crohn's disease: data from the CREdIT registry.
    Inflamm Bowel Dis. 2026 Oct 28:izag224. doi: 10.1093.
    PubMed         Abstract available
    
    
13. MA X, Shan Q
    Risk of serious infection, myocardial infarction, stroke, and thromboembolic events in patients in the United States with ulcerative colitis treated with tofacitinib compared with biologic treatments.
    Inflamm Bowel Dis. 2026 Oct 26:izag226. doi: 10.1093.
    PubMed        
    
    
14. GIANFRANCESCO MA, Curtis JR
    Reply to "Risk of serious infection, myocardial infarction, stroke, and thromboembolic events in patients in the United States with ulcerative colitis treated with tofacitinib compared with biologic treatments".
    Inflamm Bowel Dis. 2026 Oct 24:izag220. doi: 10.1093.
    PubMed        
    
    
15. KELLERMAYER R, Masand P
    Handheld intestinal ultrasound and the point-of-care question in pediatric IBD: a commentary.
    Inflamm Bowel Dis. 2026;32:2237-2241.
    PubMed         Abstract available
    
    
16. REVES J, Guedes A, Bravo AC, Sa M, et al
    Importance of higher infliximab trough level maintenance compared with the HLA-DQA1*05 polymorphism in preventing anti-infliximab antibodies and loss of response to infliximab.
    Inflamm Bowel Dis. 2026;32:2232-2236.
    PubMed         Abstract available
    
    

    
    J Crohns Colitis

17. JEFREMOW A, Neurath MF
    Cyclosporine A in acute severe ulcerative colitis: practical considerations for dosing, monitoring, and prophylaxis.
    J Crohns Colitis. 2026;20:jjag185.
    PubMed        
    
    
18. KUMAR L, Hanly M, Fennessy A, O'Morain N, et al
    Development of a core outcome set for IBD patients with stomas.
    J Crohns Colitis. 2026;20:jjag157.
    PubMed         Abstract available
    
    
19. POHL K, Nigam GB, Kent A, East JE, et al
    UK national analysis of colonoscopy quality in inflammatory bowel disease surveillance: a National Endoscopy Database (NED) cohort study.
    J Crohns Colitis. 2026;20:jjag126.
    PubMed         Abstract available
    
    
20. GISBERT JP, Lucendo AJ, Chaparro M
    Hepatic steatosis in inflammatory bowel disease: practical questions and evidence-based answers.
    J Crohns Colitis. 2026;20:jjag175.
    PubMed         Abstract available
    
    
21. PIGA G, Amiot A, Bonnet J, Villani AP, et al
    Noninfectious skin lesions in Crohn's disease patients treated with ustekinumab: a multicenter observational retrospective GETAID study.
    J Crohns Colitis. 2026;20:jjag177.
    PubMed         Abstract available
    
    

    
    J Immunol

22. MOUCHTARIDI E, Halfvarson J, Mak JYW, Fairlie DP, et al
    Altered MAIT cell activation characteristics with impaired IL-10 and IL-17A response programs in active Crohn's disease.
    J Immunol. 2026;215:vkag271.
    PubMed         Abstract available
    
    

    
    PLoS One

23. ZHANG L, Liu J, Liang C, Han Q, et al
    Exploratory baseline mucosal transcriptomics and vedolizumab response in ulcerative colitis.
    PLoS One. 2026;21:e0361301.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum